血根樹鹼硝酸鹽 | 4752-86-7

• 物质功能分类: 天然产物 - 生物碱
• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 苯并菲啶生物碱
• 中文名称: 血根樹鹼硝酸鹽
• 中文别名: 硝酸血根碱
• 英文名称: Sanguinarine nitrate
• 英文别名: 24-methyl-5,7,18,20-tetraoxa-24-azoniahexacyclo[11.11.0.02,10.04,8.014,22.017,21]tetracosa-1(24),2,4(8),9,11,13,15,17(21),22-nonaene;nitrate
• CAS: 4752-86-7
• 化学式: C20H14N2O7
• 分子量: 394.3
• InChiKey: RBKBIPRGKKUAFZ-UHFFFAOYSA-N

物化性质

• 熔点：
  227°C (dec.)

计算性质

• 辛醇/水分配系数(LogP)：
  3.19
• 重原子数：
  29
• 可旋转键数：
  0
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  104
• 氢给体数：
  0
• 氢受体数：
  7

安全信息

• 安全说明：
  S1,S22,S45
• 危险类别码：
  R25

文献信息

• Method for inhibiting bone resorption and collagenase release
  申请人：VIPONT PHARMACEUTICAL, INC.

  公开号：EP0326627A1

  公开（公告）日：1989-08-09

  Method of inhibiting bone resorption and collagenase release in mammalian periodontal subjects using a benzo-c-phenanthridine alkaloid compound.

  使用苯并-c-菲啶生物碱化合物抑制哺乳动物牙周骨吸收和胶原酶释放的方法。
• Method for inhibiting the release of histamine
  申请人：VIPONT PHARMACEUTICAL, INC.

  公开号：EP0326628A1

  公开（公告）日：1989-08-09

  The present invention deals with the inhibition of histamine release from mammalian mast cells by contacting such cells with sanguinarine, a benzophenanthridine alkaloid.

  本发明涉及通过将哺乳动物肥大细胞与一种二苯并菲类生物碱--桑吉那林接触，抑制此类细胞释放组胺。
• Production of high purity alkaloids
  申请人：VIPONT PHARMACEUTICAL, INC.

  公开号：EP0379623A1

  公开（公告）日：1990-08-01

  A method for extracting valuable alkaloid mate­rials from plants containing the same comprising slurrying the comminuted plant material in a mixture of water and a cosolvent at a pH of 8.5, adding a nonpolar, water-insoluble, solvent to dissolve the alkaloid, washing the nonpolar phase with acidulated water to convert the alkaloid to the imminium ion or acid salt form, precipitating the alkaloid, and recovering and drying the alkaloid.

  一种从含有有价值生物碱的植物中提取有价值生物碱材料的方法，包括在 pH 值为 8.5 的水和共溶剂混合物中将粉碎的植物材料浆化，加入非极性、不溶于水的溶剂以溶解生物碱，用酸化水洗涤非极性相以将生物碱转化为铵离子或酸性盐形式，沉淀生物碱，以及回收和干燥生物碱。
• Pharmaceutical composition containing glycyrrhetinic acid and phenanthridine alkaloids
  申请人：KEMIPROGRESS s.r.L.

  公开号：EP0565495A1

  公开（公告）日：1993-10-13

  The invention relates to pharmaceutical compositions for the treatment and prevention of cutaneous and oral mucous membrane inflammations comprising 18β-glycyrrhetic acid, benzophenanthridine alkaloids and possibly a suitable salt.

  本发明涉及用于治疗和预防皮肤和口腔粘膜炎症的药物组合物，其中包含 18β-甘草亭酸、苯并菲啶生物碱和可能的适当盐类。
• Methods of screening compositions for G protein-coupled receptor desensitization inhibitory activity
  申请人：Oakley H. Robert

  公开号：US20050136431A1

  公开（公告）日：2005-06-23

  The methods of the present invention allow the screening of a test composition for non-receptor-specific GPCR desensitization inhibitory activity. The methods involve screening a test composition for an indication of GPCR desensitization inhibitory activity against two or more GPCRs that are different from each other. When there is an indication that a particular test composition has GPCR desensitization inhibitory activity with respect to each of the two or more GPCRs that are different from one another, then, according to the present invention, there is an indication that the test composition has non-receptor-specific GPCR desensitization inhibitory activity.

  本发明的方法可以筛选出具有非受体特异性 GPCR 脱敏抑制活性的试验组合物。这些方法包括筛选试验组合物，以确定其对两个或多个彼此不同的 GPCR 具有 GPCR 脱敏抑制活性。当有迹象表明某种特定的试验组合物对两个或多个彼此不同的 GPCR 具有 GPCR 脱敏抑制活性时，根据本发明，就表明该试验组合物具有非受体特异性 GPCR 脱敏抑制活性。